Phenomenex Inc. has announced that it will begin to directly serve customers in Switzerland following the mutually agreed upon end of its 26-year-old partnership with local distributor Brechbühler AG.
Phenomenex Inc. has announced that it will begin to directly serve customers in Switzerland following the mutually agreed upon end of its 26-year-old partnership with local distributor Brechbühler AG.
Phenomenex customers in Switzerland will now have access to a variety of services such as comprehensive technical training and support services, live technical chat, online ordering, increased product availability, and rapid shipping times.
Shane Lyons, President of Phenomenex commented: “We will always be indebted to Brechbühler AG for such a successful partnership. Going forward, we are excited for the opportunity to directly serve our Swiss customers with our world-class technical support and customer intimate service model. We are thrilled to be expanding our global operations to better serve our customers.”
Distribution changes came into effect on 1st September 2017.
For more information on Phenomenex, please visit www.phenomenex.com
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.